Toes RE - Search Results

1

Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells.

Ludewig B, McCoy K, Pericin M, Ochsenbein AF, Dumrese T, Odermatt B, Toes RE, Melief CJ, Hengartner H, Zinkernagel RM. Ludewig B, et al. Among authors: toes re. J Immunol. 2001 Mar 15;166(6):3678-87. doi: 10.4049/jimmunol.166.6.3678. J Immunol. 2001. PMID: 11238607

2

Decreased tumor surveillance in perforin-deficient mice.

van den Broek ME, Kägi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Melief CJ, Zinkernagel RM, Hengartner H. van den Broek ME, et al. J Exp Med. 1996 Nov 1;184(5):1781-90. doi: 10.1084/jem.184.5.1781. J Exp Med. 1996. PMID: 8920866 Free PMC article.

3

Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.

Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ. Toes RE, et al. J Immunol. 1996 May 15;156(10):3911-8. J Immunol. 1996. PMID: 8621930

4

Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells.

Toes RE, van der Voort EI, Schoenberger SP, Drijfhout JW, van Bloois L, Storm G, Kast WM, Offringa R, Melief CJ. Toes RE, et al. J Immunol. 1998 May 1;160(9):4449-56. J Immunol. 1998. PMID: 9574550

5

Cross-priming of CTL responses in vivo does not require antigenic peptides in the endoplasmic reticulum of immunizing cells.

Schoenberger SP, van der Voort EI, Krietemeijer GM, Offringa R, Melief CJ, Toes RE. Schoenberger SP, et al. Among authors: toes re. J Immunol. 1998 Oct 15;161(8):3808-12. J Immunol. 1998. PMID: 9780143

6

MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells.

Sijts AJ, Standera S, Toes RE, Ruppert T, Beekman NJ, van Veelen PA, Ossendorp FA, Melief CJ, Kloetzel PM. Sijts AJ, et al. Among authors: toes re. J Immunol. 2000 May 1;164(9):4500-6. doi: 10.4049/jimmunol.164.9.4500. J Immunol. 2000. PMID: 10779750

7

Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance.

den Boer AT, Diehl L, van Mierlo GJ, van der Voort EI, Fransen MF, Krimpenfort P, Melief CJ, Offringa R, Toes RE. den Boer AT, et al. Among authors: toes re. J Immunol. 2001 Sep 1;167(5):2522-8. doi: 10.4049/jimmunol.167.5.2522. J Immunol. 2001. PMID: 11509591

8

An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene.

Toes RE, Offringa R, Blom RJ, Brandt RM, van der Eb AJ, Melief CJ, Kast WM. Toes RE, et al. J Immunol. 1995 Apr 1;154(7):3396-405. J Immunol. 1995. PMID: 7534797

9

Peptide-based cancer vaccines.

Melief CJ, Offringa R, Toes RE, Kast WM. Melief CJ, et al. Among authors: toes re. Curr Opin Immunol. 1996 Oct;8(5):651-7. doi: 10.1016/s0952-7915(96)80081-1. Curr Opin Immunol. 1996. PMID: 8902390 Review.

10

Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.

Sutmuller RP, Schurmans LR, van Duivenvoorde LM, Tine JA, van Der Voort EI, Toes RE, Melief CJ, Jager MJ, Offringa R. Sutmuller RP, et al. Among authors: toes re. J Immunol. 2000 Dec 15;165(12):7308-15. doi: 10.4049/jimmunol.165.12.7308. J Immunol. 2000. PMID: 11120866

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

449 results

Search Page